Glaucoma Market was estimated to be USD 4,466 million in 2021, Delveinsight

The Glaucoma Market Insights report from DelveInsight provides a thorough understanding of the Glaucoma market size by treatment, epidemiology, emerging therapies, market share of the various therapies, and the current and forecasted Glaucoma market sizes from 2019 to 2032 divided into the 7MM (the USA, EU5 (Germany, France, Italy, Spain, and the UK), and Japan) regions.

Glaucoma: An Overview
Glaucoma is a disease that damages the eye's optic nerve. It usually happens when fluid builds up in the front part of the eye. That extra fluid increases the pressure in eye, damaging the optic nerve. The condition is a leading cause of blindness for people over 60 years old. But blindness from glaucoma can often be prevented with early treatment.

Request for sample and discover more about the Glaucoma report offerings- https://www.delveinsight.com/sample-request/glaucoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Regions Covered in the Report
• The United States
• EU-5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Key Takeaways from Glaucoma Market Report
• "As per DelveInsight's analysis, a higher percentage of diagnosed prevalence was observed for females, in comparison to males, in all the 7MM countries. The highest proportion of Gluacoma cases was observed in 40 years and above age group in the 7MM. Among the major types of Glaucoma, i.e., open-angle and close-angle glaucoma, the former one accounts for a higher number of diagnosed Glaucoma cases"
• The total diagnosed prevalent population of Glaucoma in the 7MM was 11,048,000 in 2021, which is expected to increase in the forecast period (2022-2032).
• Among the five European countries, Germany had the highest diagnosed prevalent population of Glaucoma with 1,115,113 cases, followed by Italy and France in 2021. On the other hand, Spain had the lowest.
• Japan had 3,387,932 diagnosed prevalent cases for Glaucoma in 2021.
• In 2021, in the United States, open-angle glaucoma was more prominent than closed angle with total cases of 3,119,031 cases of open angle glaucoma. Out of these total open-angle glaucoma cases, 2,807,128 cases were of primary open-angle glaucoma whereas secondary open-angle glaucoma had 311,903 cases in the United States in 2021.
• There were a total of 273,002 cases of steroid induced glaucoma in Japan in 2021. These cases are anticipated to decrease during the forecast period.
• Highest number of cases of glaucoma in the 7MM wre observed in the 40years and above age group with a total of 10,099,987 cases in 2021. The least number of cases were observed in 2 to 60 years, genetic predisposition, certain eye characteristics (such as a pupillary defect, thin cornea, myopia), low educational status, smoking, African descent, and visual problems are associated with this indication and treatment pattern varies accordingly.

Glaucoma Types
There are two major types of glaucoma, i.e., Primary open-angle glaucoma (POAG), and Angle-closure /glaucoma closed-angle glaucoma/narrow-angle glaucoma. The "angle" in both cases refers to the drainage angle inside the eye that controls the outflow of the watery fluid (aqueous) which is being produced inside the eye.

Glaucoma Emerging Drugs
PDP-716: Sun Pharma Advanced Research Company Limited (SPARC)
PDP-716 is a novel, once-a-day formulation of Brimonidine developed using SPARC's TearActTM Technology for treatment of Glaucoma. The drug provides dosing convenience to patients compared to a currently marketed product that requires thrice-a-day dosing. The drug contains brimonidine which is one of the most commonly used treatments of glaucoma and ocular hypertension. The company has recently released the topline results for the Phase III clinical trials for PDP-716 in 2021.

TC-002 : TearClear
TC-002 is a preservative-free latanoprost ophthalmic solution that is being developed by TearClear for the treatment of glaucoma. TearClear is the first and only company to develop products that deliver preservative-free drops to the eye while maintaining BAK preserved formulations in the bottle.

Get to know more about the Glaucoma Market Report offering- https://www.delveinsight.com/report-store/glaucoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Glaucoma Market Size
The Glaucoma market size in the 7MM was estimated to be USD 4,466 million in 2021. In 2021, the least revenue generating class for the treatment of glaucoma was selective EP2 receptor agonists, which generated a total revenue of USD 25 million in the 7MM.

Glaucoma Market Companies
• Aerie Pharmaceuticals
• Sun Pharma Advanced Research Company Limited
• Santen Pharmaceutical/Ube Industries, Bausch and Lomb
• Western Therapeutics Institute (DWTI)/Kowa LTD.
• Alcon Research
• Merck Sharp & Dohme Corp
• Novartis/Alcon Research
• Allergan
• Senju Pharmaceuticals, and several others

Glaucoma Drugs
• Rocklatan
• Rhopressa
• Xelpros (latanoprost ophthalmic emulsion) 0.005%
• Eybelis Ophthalmic Solution 0.002% (DE-117
• Omidenepag isopropyl)
• Vyzulta, Tapcom/DE-111 (Tafluprost/timolol maleate)
• Glanatec
• Simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2%
• Zioptan (tafluprost)
• DuoTrav PQ (travoprost/timolol)
• Travatan Z (travoprost ophthalmic solution) 0.004%
• Lumigan 0.01% (bimatoprost ophthalmic solution)
• Durysta (Bimatoprost SR)
• AILAMIDE
• Aibeta, and several others

View Detailed Research Report Here @ https://www.delveinsight.com/report-store/glaucoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Glaucoma Market Report Introduction
3. Overview at a Glance
4. Executive Summary of Glaucoma
5. Glaucoma Market Disease Background and Overview
6. Treatment Algorithm for Open-Angle Glaucoma
7. Glaucoma Treatment
8. Glaucoma Epidemiology and Patient Population
9. Organizations contributing towards Open-Angle Glaucoma (OAG)
10. Patient Journey
11. Glaucoma Case Reports
12. Glaucoma Marketed Products
13. Glaucoma Emerging Therapies
14. Glaucoma: Seven Major Market Analysis
15. KOL Views
16. Glaucoma Market Drivers
17. Glaucoma Market Barriers
18. SWOT Analysis
19. Glaucoma Unmet Needs
20. Glaucoma Reimbursement
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
24. About DelveInsight

Get in touch with our Business Expert- https://www.delveinsight.com/sample-request/glaucoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Contact Us
Yash
info@delveinsight.com

About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.